A Novel Generative AI-Designed T-Cell Receptor Bispecific for Cancer Immunotherapy

Time: 4:00 pm
day: Conference Day Two


  • Application of the proprietary machine learning platform, EMLyTM , for TCR discovery leading to the generation of a lead PRAME TCR
  • TCR engineering using EMLyTM for rapid affinity enhancement of the parent molecule by more than 5 million-fold
  • Development of a functional TCR bispecific from this lead molecule, and current advancement towards preclinical phase